Genomics

#AI / data analytics / healthtech / informatics #Bioinformatics #Drug discovery #Genomics #QUIAGEN

QIAGEN expands AI-powered bioinformatics for research and drug discovery   

QIAGEN’s new artificial intelligence (AI) capabilities will reportedly help researchers analyse complex biological and genomic data faster while keeping the scientific evidence behind the results visible.  The expansion includes IPA Investigator, a new AI research companion for QIAGEN Ingenuity Pathway Analysis (IPA), and the new QIAGEN Discovery… Read More

#News

#Advertorial #Epigenomics #Genomics #Mutliomics #Neurological disease #Sampled

From genomics to multiomics: A broader view of neurological disease

In this paid-for advertorial for the Fall 2026 issue of DDW, Sampled shares insight on neurological disease with a genomics and multiomics lens.  Genomic testing can identify drivers of neurological disease, but many variants remain difficult to interpret. Multiomics helps to close this gap by connecting genetic findings with… Read More

#Exclusive Content

#Drug discovery #Genetics #Genomics #Target discovery

From disease genetics to more effective medicines 

Dr James Heward, VP Functional Genomics at Nucleome Therapeutics, discusses what could be the missing link in the chain of causality from patient to target to drug.   The fundamental question that stalks every drug discovery project is “will this drug fail?” Most do. There is no single reason for more than 90% of clinical… Read More

#Exclusive Content

AI and genomics
#Artificial intelligence (AI) #Funding #Genomics #Innovate UK #OutSee

OutSee receives Innovate UK grant for agentic AI pilot study

Genomics drug discovery company OutSee has been awarded funding through Innovate UK’s Investor Partnership Grant, jointly provided by Innovate UK and Empirical Ventures.   The grant will enable OutSee to conduct a pilot study for a prototype target validation sub-system, designed for initial triage of potential drug targets… Read More

#News

Cancer cells
#Drug discovery #Epigenetics #Genomics #Oncology

How Oryzon Genomics is using epigenetics to tackle cancer  

DDW Editor Reece Armstrong speaks to Dr Carlos Buesa, Founder and CEO of Oryzon Genomics, about epigenetic approaches to treating cancer and the company’s current journey within drug discovery and development.   RA: Can an epigenetic approach help tackle aggressive cancers and those with poor prognoses?  CB: Yes. Many aggressive cancers are… Read More

#Exclusive Content

#AI #Drug discovery #Genomics #Multiomics #Transcriptomics

Advances in genomics for drug discovery 

DDW Editor Reece Armstrong speaks to Michelle Carlson about overall advances in genomics and the integration of emerging technologies to create more drug discovery and development opportunities.  RA: How is long-read sequencing enabling greater clinical research… Read More

#Exclusive Content

Genomics
#ALS #Genomics #Longitude Prize #OutSee

OutSee receives Discovery Award from Longitude Prize on ALS 

OutSee has received a Discovery Award from the Longitude Prize on ALS, the genomics and drug discovery company has announced.  The award will grant OutSee access to genomic data from 9,000 amyotrophic lateral sclerosis (ALS) patients, in addition to £100,000 ($134,000) in funding, supporting a research project… Read More

#News

Francis Crick Institute
#DNA #Genomics #The Francis Crick Institute

Crick set to open UK’s first ancient DNA exhibition 

The Francis Crick Institute is set to house the UK’s first ancient DNA exhibition exploring human evolution and disease.  The exhibition, set to open on 16 July 2026, is led by researchers at the Crick’s Ancient Genomics Laboratory.  ‘We Go Way Back’ will uncover findings from… Read More

#News

#AI #Business #Genomics #Lab automation #SLAS2026

Lab automation strong despite global challenges

The world of drug discovery definitely kept us on our toes last year. Uncertainty in the market, not helped by the challenges created by changes in US drug pricing and tariffs, led to spending dips and nervousness throughout the sector.   SLAS2026 is a key point in the… Read More

#Exclusive Content #Opinion

Handshake jigsaw puzzle
#Autoimmune disease #Genomics #T cell

Genomics and Greywolf partner on autoimmune disease treatments 

Techbio company Genomics has partnered with biotech company Greywolf Therapeutics to advance novel antigen modulation treatments to treat autoimmune diseases.  Under the agreement, Genomics is set to curate and analyse large-scale genetic datasets to assess how variants of the ERAP (Endoplasmic Reticulum Aminopeptidases) enzymes influence disease risk across… Read More

#Business & Investment #News

#AI #Genomics #PacBio

Genomics initiative could boost AI-designed therapeutics 

A new initiative is set to generate and model biological data at the trillion-gene scale, paving the way to scale AI-designed therapeutics.  The Trillion Gene Atlas, developed by Basecamp Research in collaboration with Anthropic, Ultima Genomics, PacBio, and NVIDIA AI infrastructure aims to expand known evolutionary genetic diversity… Read More

#News

Liquid handler in laboratory
#Genomics #Sample preparation #SPT Labtech

SPT Labtech and Illumina to develop genomics platform 

SPT Labtech has announced a strategic collaboration with Illumina to develop a novel automated sample preparation platform in genomics.  The platform, designed to streamline and standardise genomics workflows across decentralised healthcare environments, will support laboratories using Illumina’s MiSeq i100 benchtop sequencing system. The system offers more accessible high-quality next-generation sequencing… Read More

#Business & Investment #News

Genetic research
#Genetic diseases #Genomics

Genomics technology could ‘end diagnostic odysseys’   

Illumina has launched its TruPath Genome to provide researchers with a more complete picture of genomics alterations in genetic disease.  The company claims the technology fully phases more than 98% of genes, eliminating traditional library prep and generating 16 whole genomes per day in 10 minutes of hands-on time. … Read More

#News